
    
      A double blind randomized study of celecoxib 400 mg bid versus placebo in newly diagnosed
      breast cancer. Assessment of modulation of tissue markers (Ki-67, ER, VEGF, PR, etc.) and
      serum markers (estradiol, estrone, SHBG, etc.).
    
  